Elevated Serum Low-Density Lipoproteins-Cholesterol Levels and B1B2/B2B2 <i>CETP</i> Genotype Are Positively Associated with Nonalcoholic Fatty Liver Disease in Women with Gallstone Disease-Reference-Cited by-同舟云学术

Elevated Serum Low-Density Lipoproteins-Cholesterol Levels and B1B2/B2B2 CETP Genotype Are Positively Associated with Nonalcoholic Fatty Liver Disease in Women with Gallstone Disease

Published:2023-02-01 Issue:1 Volume:21 Page:41-47
ISSN:1540-4196
Container-title:Metabolic Syndrome and Related Disorders
language:en
Short-container-title:Metabolic Syndrome and Related Disorders

Author:

Perez-Robles Mariana¹^ORCID,Campos-Perez Wendy¹,Rivera-Valdés Juan José¹,Franco-Topete Ramón Antonio²,Navarrete-Medina Eduardo Miguel²,Maldonado-González Monserrat³,Ruíz-Madrigal Bertha³,Rodríguez-Reyes Sarai Citlalic¹,Martinez-Lopez Erika¹^ORCID

Affiliation:

1. Instituto de Nutrigenética y Nutrigenómica Traslacional, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada, Guadalajara, Jalisco, Mexico.

2. Departamento de Patología y Anatomía, Hospital Civil de Guadalajara “Juan I. Menchaca,” Guadalajara, Jalisco, Mexico.

3. Laboratorio de Investigación en Microbiología, Departamento de Microbiología y Patología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/met.2022.0010

Reference55 articles.

1. Prevalencia y relación de esteatosis hepática con perfil lipídico y hepático en pacientes de chequeo médico

2. Nonalcoholic Steatohepatitis

3. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

4. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

5. Long-term follow-up of patients with NAFLD and elevated liver enzymes

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases;Frontiers in Medicine;2023-02-02